Tamoxifen and Telmisartan Interaction: Avoid | Peptide Database

Join others researching Ketoconazole — share findings, ask questions, and learn from real experiences Ketoconazole is an FDA-approved azole antifungal that has gained widespread use as a topical adjunct in hair loss treatment. Available as a 1-2% medicated shampoo, ketoconazole disrupts DHT binding at the hair follicle and reduces scalp inflammation driven by the fungus Malassezia, both of which contribute to follicular miniaturization. It is a core component of the widely referenced "big 3" hair loss stack alongside finasteride and minoxidil. While ketoconazole was originally developed as a systemic antifungal for conditions like fungal infections and seborrheic dermatitis, its topical anti-androgenic properties at the scalp level have made it a practical and low-risk addition to hair loss regimens. When used as a shampoo, systemic absorption is negligible, keeping the side effect profile limited to occasional local irritation. Ketoconazole works through multiple pathways relevant to hair loss. As an azole antifungal, it inhibits the enzyme lanosterol 14-alpha-demethylase, disrupting ergosterol synthesis and killing Malassezia fungi that colonize the scalp and contribute to inflammation and seborrheic dermatitis. This anti-inflammatory effect reduces the chronic follicular inflammation associated with androgenetic alopecia. Independently, ketoconazole has demonstrated topical anti-androgenic activity by disrupting the binding of dihydrotestosterone (DHT) and other androgens to receptors at the hair follicle. Some evidence also suggests it may interfere with local androgen synthesis pathways. Unlike systemic anti-androgens such as finasteride, ketoconazole shampoo exerts these effects locally at the scalp without meaningful systemic hormonal changes, making it a well-tolerated complement to oral DHT-blocking therapies.

Silenor (doxepin 3 mg and 6 mg) is FDA-approved for the treatment of insomnia characterized by difficulty with sleep maintenance. Clinical trials demonstrated that ultra-low dose doxepin significantly improved sleep maintenance (wake after sleep onset) and total sleep time without next-morning residual effects at the 3 mg dose, and with minimal residual effects at 6 mg. At higher doses (75-300 mg), doxepin is FDA-approved for the treatment of depression and anxiety associated with depression. However, this use is largely historical, as newer antidepressants with more favorable side effect profiles have supplanted TCAs for most patients. The antidepressant dosing range is entirely separate from the ultra-low dose sleep application. Clinical data supports the efficacy and safety of ultra-low dose doxepin for long-term insomnia management. Unlike many hypnotics, doxepin at 3-6 mg maintains its efficacy over months of continuous use without dose escalation, making it suitable for chronic insomnia in patients who need a sustainable, long-term solution. Ultra-low dose doxepin is one of the few sleep medications with specific safety and efficacy data in elderly patients. The 3 mg dose is recommended for older adults and has been shown to improve sleep maintenance without the falls, cognitive impairment, and next-day sedation risks associated with benzodiazepines and Z-drugs in this population.